|
Synonyms: LY-3853113 | LY-CoV-1404 | LY-CoV1404 | LY3853113
Compound class:
Antibody
Comment: Bebtelovimab (LY3853113) is a SARS-CoV-2-neutralising monoclonal antibody that binds to the virus' spike surface glycoprotein [2]. It was reported to be effective against the delta and early omicron variants (B.1.617.2 and B.1.1.529 respectively). As of July 2022 bebtelovimab was the only available mAb to show preserved in vitro activity against the omicron BA.4 and BA.5 subvariants that were superceding previous omicron subvariants at that time [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Bebtelovimab is one of the mAbs being evaluated in clinical trial NCT04634409. It was granted FDA emergency use authorisation (EUA) on 11 February 2022. Its use is indicated for COVID-19 patients (with mild to moderate symptoms) who are at high risk of progressing to severe disease. The developers have not submitted bebtelovimab to regulatory agencies anywhere outside of the USA. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04634409 | A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness | Phase 2 Interventional | Eli Lilly and Company | ||
